[1] |
Macías I, Alcorta-Sevillano N, Rodríguez CI, et al. Osteoporosis and the potential of cell-based therapeutic strategies[J]. Int J Mol Sci, 2020, 21:1653-1676.
|
[2] |
Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors[J]. Nat Rev Rheumatol, 2020, 16:380-390.
|
[3] |
Raterman HG, Bultink IE, Lems WF. Osteoporosis in patients with rheumatoid arthritis: an update in epidemiolo-gy, pathogenesis, and fracture prevention[J]. Expert Opin Pharmacother, 2020, 21:1725-1737.
|
[4] |
Wang D, Cai G, Wang H, et al. TRAF3, a target of microRNA-363-3p, suppresses senescence and regulates the balance between osteoblastic and adipocytic differentiation of rat bone marrow-derived mesenchymal stem cells[J]. Stem Cells Dev,2020, 29:737-745.
|
[5] |
Del Real A, López-Delgado L, Saóudo C, et al. Long noncoding RNAs as bone marrow stem cell regulators in osteoporosis[J]. DNA Cell Biol, 2020, 39:1691-1699.
|
[6] |
Wang CG, Hu YH, Su SL, et al. LncRNA DANCR and miR-320a suppressed osteogenic differentiation in osteoporosis by directly inhibiting the Wnt/β-catenin signaling pathway[J]. Exp Mol Med, 2020, 52:1310-1325.
|
[7] |
Teng Z, Zhu Y, Zhang X, et al. Osteoporosis is characterized by altered expression of exosomal long non-coding RNAs[J]. Front Genet, 2020, 11:566959-566972.
|
[8] |
Kou J, Zheng X, Guo J, et al. MicroRNA-218-5p relieves postmenopausal osteoporosis through promoting the osteoblast differentiation of bone marrow mesenchymal stem cells[J]. J Cell Biochem, 2020, 121:1216-1226.
|
[9] |
Ko NY, Chen LR, Chen KH. The role of microRNA and long-non-coding RNA in osteoporosis[J]. Int J Mol Sci,2020, 21:4886-4903.
|
[10] |
范琳媛, 李红凌. 长链非编码RNAs调控骨稳态研究进展[J]. 基础医学与临床, 2020, 40: 115-119.
|
[11] |
Li Z, Hong Z, Zheng Y, et al. An emerging potential therapeutic target for osteoporosis: lncRNA H19/miR-29a-3p axis[J]. Eur J Histochem, 2020, 64:3155-3160.
|
[12] |
Feng J, Wang JX, Li CH. LncRNA GAS5 over-expression alleviates the development of osteoporosis through promot-ing osteogenic differentiation of MSCs via targeting microRNA-498 to regulate RUNX2[J]. Eur Rev Med Pharmacol Sci, 2019, 23:7757-7765.
|
[13] |
Xie W, Li F, Han Y, et al. Neuropeptide Y1 receptor antagonist promotes osteoporosis and microdamage repair and enhances osteogenic differentiation of bone marrow stem cells via cAMP/PKA/CREB pathway[J]. Aging (Albany NY),2020, 12:8120-8136.
|